• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

EPTIFIBATIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • EPTIFIBATIDE chembl:CHEMBL1174 Approved

    Alternate Names:

    EPTIFIBATIDE
    INTEGRILIN
    INTEGRELIN®
    N(6)-AMIDINO-N(2)-(3-MERCAPTOPROPIONYL)-L-LYSYLGLYCYL-L-ALPHA-ASPARTYL-L-TRYPTOPHYL-L-PROLYL-L-CYSTEINAMIDE, CYCLIC(1-6)-DISULFIDE
    C68-22
    S(1),S(6)-CYCLO[N(6)-CARBAMIMIDOYL-N(2)-(3-SULFANYLPROPANOYL)-L-LYSYLGLYCYL-L-ALPHA-ASPARTYL-L-TRYPTOPHYL-L-PROLYL-L-CYSTEINAMIDE]
    chemidplus:188627-80-7
    chembl:CHEMBL1174
    rxcui:75635
    pubchem.compound:448812
    drugbank:00063

    Drug Info:

    Drug Class platelet aggregation inhibitors
    Year of Approval 1998
    FDA Approval approved
    Drug Class peptide
    Drug Indications antiplatelet agent
    (2 More Sources)

    Publications:

    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Fischer et al., 2005, Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis., Biomaterials
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Schrör et al., 2003, Comparative pharmacology of GP IIb/IIIa antagonists., J. Thromb. Thrombolysis
    Auer et al., 2003, [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease]., Herz
    Weber et al., 2002, No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors., Pharmacogenetics
    Amoroso et al., 2001, Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease., J. Cardiovasc. Pharmacol.
    Schwarz et al., 2004, Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61)., J. Pharmacol. Exp. Ther.
  • EPTIFIBATIDE   ITGB3

    Interaction Score: 10.6

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name eptifibatide,Integrilin
    Novel drug target Established target
    Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor

    PMIDs:
    20938371 15860200 10592235 14618072 12928738 12360110 11588534 14617694


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • EPTIFIBATIDE   ITGA2B

    Interaction Score: 5.5

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name eptifibatide,Integrilin
    Novel drug target Established target
    Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor

    PMIDs:
    20938371


    Sources:
    TdgClinicalTrial ChemblInteractions PharmGKB

  • EPTIFIBATIDE   FGG

    Interaction Score: 4.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • EPTIFIBATIDE   FGB

    Interaction Score: 3.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • EPTIFIBATIDE   FGA

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • TEND: EPTIFIBATIDE

    • Version: 01-August-2011

    Alternate Names:
    EPTIFIBATIDE Primary Drug Name

    Drug Info:
    Year of Approval 1998
    Drug Class platelet aggregation inhibitors

    Publications:

  • TdgClinicalTrial: EPTIFIBATIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiplatelet agent
    Drug Class peptide
    FDA Approval approved

    Publications:

  • PharmGKB: eptifibatide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics

  • TTD: Eptifibatide

    • Version: 2020.06.01

    Alternate Names:
    D09ZIO TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1174

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1174

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21